Endologix Inc. announced that the first patient has been enrolled in the company's U.S. clinical trial to evaluate the Ventana(TM) Fenestrated Stent Graft System for the endovascular repair of juxtarenal and pararenal abdominal aortic aneurysms (AAAs). The procedure was performed by Matthew Eagleton, MD (Cleveland Clinic Foundation, Department of Vascular Surgery). National Principal Investigator Daniel G. Clair, MD (Chairman, Department of Vascular Surgery, Cleveland Clinic Foundation) proctored the procedure. The multicenter, prospective, single arm Ventana clinical trial was approved by the U.S. Food and Drug Administration under an Investigational Device Exemption (IDE) for conduct at up to 25 U.S. clinical sites and involving 122 patients. The trial is intended to support a future premarket approval (PMA) application to the FDA to provide reasonable assurances of safety and effectiveness for the Ventana System for the endovascular repair of juxtarenal and pararenal aneurysms in selected patients. The trial primary endpoints will evaluate safety (major adverse events) at 30 days and effectiveness (treatment success) at one year, with continuing follow-up to five years.